Advertisement


Francesca M. Gay, MD, on Multiple Myeloma: Results From the Forte Trial

2018 ASH Annual Meeting & Exposition

Advertisement

Francesca M. Gay, MD, of GIMEMA, European Myeloma Network, discusses study findings on the use of carfilzomib in induction combination regimens with autologous transplantation, and consolidation regimens in newly diagnosed multiple myeloma (Abstract 121).



Related Videos

Lymphoma

Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with C...

Lymphoma

John P. Leonard, MD, on NHL: Results From the AUGMENT Trial

John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or...

Issues in Oncology
Symptom Management

Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromb...

Leukemia
Lymphoma
Immunotherapy

Julie Vose, MD, MBA, and Merav Bar, MD, on CAR T-Cell Therapy: Late Effects of CD19-Targeted Treatment

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Merav Bar, MD, of the Fred Hutchinson Cancer Research Center, discuss study findings on the ...

Lymphoma

Anas Younes, MD, on DLBCL: Phase III Trial Results

Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in peop...

Advertisement

Advertisement



;
Advertisement